Search

everythinglearnresearchcommunity

for

Search:↓

Facial hair loss and psychosocial issues are crucial in deciding treatment for alopecia areata.

Ritlecitinib effectively regrows scalp, eyebrow, and eyelash hair in Asians with alopecia areata and is safe.

Ritlecitinib is effective long-term for treating alopecia areata in teens.

Clinicians should use evidence-based tools and consider mental health when assessing alopecia areata to guide treatment.

Baricitinib is effective and safe for long-term treatment of severe alopecia areata.

Baricitinib helps regrow hair in teens with severe alopecia areata.

Alopecia areata severity and symptoms vary by race and ethnicity.

Ritlecitinib effectively promotes hair regrowth in severe and very severe alopecia areata.

Over half of alopecia areata patients in Tunisia experience depression, highlighting the need for psychological support.

Baricitinib 4 mg is effective and safe for treating severe alopecia areata.

Facebook groups play a crucial role in supporting and guiding patients on scalp cooling and hair loss during chemotherapy.

The SBN system effectively assesses alopecia areata severity and predicts its course.

Alopecia areata causes negative emotions and stress due to hair loss and emotional triggers.

Eyelash loss can temporarily occur from chemotherapy for retinoblastoma.

Ayurvedic treatment helped a woman regrow her lost eyebrow and eyelash hair.

Baricitinib effectively treats severe alopecia for up to 104 weeks.

A Jordanian family with Clouston syndrome has a common GJB6 gene mutation.

Baricitinib was effective and safe for severe hair loss treatment over 6 months.

Reducing immunosuppression and using antiviral creams improved the woman's skin condition.

Micropigmentation is a cosmetic tattooing technique for hiding skin issues and creating permanent makeup, but it can have side effects.

A child lost eyelashes on one eyelid after COVID-19, likely due to a temporary hair loss condition.

Patient-reported outcomes better reflect the quality of life impact of alopecia areata than traditional severity scores.

Baricitinib was effective in regrowing eyebrow and eyelash hair in patients with severe alopecia areata.

The goal is to create a tool for patients to report their experiences with various hair and scalp disorders.

Early recognition and treatment of VATS in transplant patients improve outcomes.

Early diagnosis and treatment of frontal fibrosing alopecia are crucial to prevent permanent hair loss.

The document concludes that successful treatment of upper and midface trauma should focus on restoring both appearance and function, with attention to facial structure, skin, and hair repair.

After chemotherapy for early breast cancer, 33.4% of patients had long-term significant hair loss, with some hair regrowth over time, but treatments for hair loss were largely ineffective.

Alopecia areata is a hair loss condition that often starts before age 30 and can affect various body parts, with unpredictable hair regrowth chances.

The book is a detailed and useful guide for doctors learning about hair transplantation.